Improved survival in multiple myeloma and the impact of novel therapies. - Wikidata - awgldk - TriplyDB

Improved survival in multiple myeloma and the impact of novel therapies.

Improved survival in multiple myeloma and the impact of novel therapies.

http://www.wikidata.org/entity/Q36478461

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma Prevalence of monoclonal gammopathy of undetermined significance: a systematic review Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Novel agents in the treatment of multiple myeloma: a review about the future Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Multiple myeloma in the very elderly patient: challenges and solutions MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens Recent advances in the field of anti-cancer immunotherapy Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Potential role of daratumumab in the treatment of multiple myeloma Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers Immunogenic targets for specific immunotherapy in multiple myeloma Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias Smoldering multiple myeloma requiring treatment: time for a new definition?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)European perspective on multiple myeloma treatment strategies in 2014 Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib Immunotherapy strategies for multiple myeloma: the present and the future Innovative agents in multiple myeloma Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials Targeted therapy for HM1.24 (CD317) on multiple myeloma cells Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma Development of Novel Immunotherapies for Multiple Myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective New investigational drugs with single-agent activity in multiple myeloma Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma Recent advances in multiple myeloma: a Korean perspective The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

P2860

Q21133524-B7F1DF74-D7BC-4D1F-A96B-2A3065A0641B Q24197999-6D379449-0195-4123-A4D1-067C6EE4497C Q24202358-D412AB32-8797-4945-9BA6-EE719B7A8B7C Q24597406-3955C9CB-EC24-42B3-96A4-766CD6AD9611 Q24598483-8562DA7B-1F4F-4C8B-917F-D699B4941831 Q24619589-23DEB21F-2642-4B40-B1D4-AC0BC5A0C7B5 Q26738944-E8ADBCBF-D69A-4520-90DC-75FDFBA9B5EB Q26745919-AF137E3B-0C5B-4654-B338-B6B3AE4D15D4 Q26745924-A58FAD94-5924-4FB0-880C-DCD09BB06A1B Q26745930-C307E206-9629-470C-832E-6C153B3B6979 Q26752991-F87E3534-EAE2-49E1-AE77-44E4C684F502 Q26765477-AC7689BF-40EA-424C-BB74-4A29B44B513F Q26767418-7832350C-81B5-4822-A78B-4A2EB4BA8D0E Q26774913-EFAACE41-6102-4798-B5E4-6AA8F73B0385 Q26775602-6165405E-7FA0-4277-99CB-52D1FDD990AF Q26785735-B72C2810-1029-41A9-9A4F-0B75744D73A1 Q26799104-5F760E51-D745-49DF-85CC-45D3B2CF593E Q26822754-C788FC20-A0E7-430F-A105-69C2E6B31928 Q26824157-F061E27E-3F44-477D-8717-2756AE141191 Q26851202-315706A6-2720-40DC-8BB3-CDDBD4F46733 Q26859007-B9470297-7CF3-4C0C-88BF-E102E4023CB5 Q26861037-4A84B9FC-17BE-43BE-997B-072C0AAA16A7 Q26996579-764C68C1-A4F6-4759-99BE-265F0DBD025A Q26998884-B70A6CB1-F0F7-42AA-A5BA-E606DA749ED4 Q27004421-50964F6C-646E-464E-AFA5-005BE5FAA6B6 Q27005966-8B7543E4-E20B-49A8-879E-527EF04FD503 Q27014143-6345E6D9-3206-4CD8-8F21-12BF3BA15CF2 Q27021939-7DC5B9E0-352B-401C-B086-3EA0AF571B9B Q27022493-A12175BF-7E5F-4B50-9B18-1FFB94C2AC6A Q27024932-EFE7C840-05BB-403D-A1A2-7665D525E496 Q27026161-79B74017-09DA-40F3-B7B9-63C58AC32BF2 Q27026478-924E2A82-723A-4B13-944A-120F3B78457D Q27316139-B7E65A57-D26A-463E-A3C0-27B11F190CCC Q28066890-8A0318B2-C80D-4507-974A-037F367CF92D Q28069789-A2FF48A7-34FE-4B8F-A875-7E4582852B25 Q28071551-2423B08F-DDBE-448C-96EC-65BB0022E9B4 Q28074490-3A0362AF-A8DF-4B0C-935E-531613F9433D Q28074521-6A6FBE7E-14A1-480D-AFBD-D29A4C06C2C7 Q28075927-1EA53F49-2FBC-4399-BD26-F2A47321BE85 Q28080823-2128348F-3841-4880-B2C3-E9C094E28296

P2860

Improved survival in multiple myeloma and the impact of novel therapies.

http://www.wikidata.org/entity/Q36478461

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Improved survival in multiple myeloma and the impact of novel therapies.

@ast

Improved survival in multiple myeloma and the impact of novel therapies.

@en

type

label

Improved survival in multiple myeloma and the impact of novel therapies.

@ast

Improved survival in multiple myeloma and the impact of novel therapies.

@en

prefLabel

Improved survival in multiple myeloma and the impact of novel therapies.

@ast

Improved survival in multiple myeloma and the impact of novel therapies.

@en

P1433

Q36478461-4B1CFA18-4B79-42C0-B2B2-D9CA2C72D3B1

P1476

Q36478461-9055CC93-AFD7-4C1E-AEFB-8FB10BAE670E

P2093

Q36478461-2481F05B-07DA-47F1-9C8B-7417B911DEF4

Q36478461-3E91540E-79D6-4A3A-96AF-A040EB7DDC4D

Q36478461-C020AD5C-B5BD-4D79-B78C-50EDBF70A321

Q36478461-D4D6598F-38AF-4C10-BCA2-389217303455

P2860

Q36478461-238724D0-9428-414F-B72C-BA6CE9BE8D81

Q36478461-36527F0F-E4CA-437A-82D4-7A2B9A064B00

Q36478461-374239B6-6CA0-4E3C-A8AF-11EBB39186DB

Q36478461-3B26FA28-F0D8-4E21-828C-5D720A5383AC

Q36478461-43EFD786-FE1E-416E-8EAE-55C71E64B08D

Q36478461-4659B836-F7CF-4233-9633-0D623B99E225

Q36478461-4D8ECAD9-BB22-4895-A904-3EAD1D412221

Q36478461-4FE29F08-0FD5-4799-BB67-AB9FF6E110A2

Q36478461-5193CFDC-C234-442D-B5DA-FC2CEF91B54A

Q36478461-6391F641-2FD6-4654-8563-9357B0388A28

P304

Q36478461-88BD0244-E90D-45A5-BF7A-944E884BFB22

P31

Q36478461-D7E1804C-8331-4CA1-8C35-E9CFD9102E3E

P356

Q36478461-DCECE673-AE45-4DEF-B848-87A7CD2AF65C

P407

Q36478461-3024A202-75C5-40CF-AAFB-4B54C7312734

P433

Q36478461-9EB16825-CB33-4B82-AE20-521C373337CC

P478

Q36478461-7C0A3B7C-5AD9-4D44-A06A-8B560DA04A00

P50

Q36478461-3E917F83-B01E-4390-968D-1CD000A79772

Q36478461-4210D1E3-E836-4C22-9D54-44D54835C41D

Q36478461-4E5FF5F6-1259-4920-91E7-BD1E858AB3E8

Q36478461-519E2D8C-C881-42D5-BAE1-6F495E4A4900

Q36478461-78E74A54-C26C-4E0A-9851-FCC4EB3E8712

Q36478461-938A13C1-6A2D-4467-B3BB-4B7E49400562

Q36478461-9696D59A-1675-4B5B-BFB8-5F0B8F2AD0AC

Q36478461-AB8D8F86-43C5-4F2C-AF68-577657432612

Q36478461-BC980901-89D6-4BD5-9532-FFDFFCB0FF3D

P577

Q36478461-ECAA5369-9336-457A-A160-56FFC6596230

P5875

Q36478461-9F7728A7-3A0B-43CD-B339-B1CFCEB177CE

P698

Q36478461-402C1FF5-9CBF-4A52-9DC7-21AAFBC2951F

P932

Q36478461-FA6078A3-8723-442D-B5DB-5DC2B77562D0

P356

BLOOD-2007-10-116129

P1433

P1476

Improved survival in multiple myeloma and the impact of novel therapies.

@en

P2093

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Philip R Greipp

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Cancer statistics, 2007

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Drug insight: thalidomide as a treatment for multiple myeloma.

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.

P304

2516-2520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-10-116129

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

Suzanne R Hayman

Steven R Zeldenrust

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5871412

http://www.w3.org/2001/XMLSchema#string

P698

17975015

http://www.w3.org/2001/XMLSchema#string

P932

2254544

http://www.w3.org/2001/XMLSchema#string